Role of β1 and β3 integrins in human: Smooth muscle cell adhesion to and contraction of fibrin clots in vitro

Circulation Research

Volumn 83, Issue 3, 1998, Pages 241-251

  Yee, Karen O ^a,b   Rooney, Michael M ^c   Giachelli, Cecilia M ^a   Lord, Susan T ^c,d   Schwartz, Stephen M ^a  

^a Department of Pathology ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Remodeling; Stenosis; Thrombosis

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CYCLOHEXIMIDE; CYCLOPEPTIDE; FIBRIN; FIBRINOGEN; FIBRONECTIN; INTEGRIN; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; VITRONECTIN; ANTIBODY; BETA1 INTEGRIN; BETA3 INTEGRIN; FIBRINOGEN RECEPTOR; FIBRONECTIN RECEPTOR; LEUKOCYTE ANTIGEN; OLIGOPEPTIDE; PENICILLAMYL GLYCYL ARGINYL GLYCYL ASPARTYL SERYL PROLYL CYSTEINYL ALANINE; PENICILLAMYL-GLYCYL-ARGINYL-GLYCYL-ASPARTYL-SERYL-PROLYL-CYSTEINYL-ALANINE; PROTEIN SYNTHESIS INHIBITOR; VITRONECTIN RECEPTOR;

AORTA MEDIA; ARTICLE; CELL ADHESION; CONTROLLED STUDY; FIBRIN CLOT; HUMAN; HUMAN CELL; IN VITRO STUDY; NEWBORN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; BLOOD CLOTTING; CELL LINE; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; MUSCLE CONTRACTION; PHYSIOLOGY; SMOOTH MUSCLE; SURFACE PROPERTY;

ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD29; BLOOD COAGULATION; CELL ADHESION; CELL LINE; CYCLOHEXIMIDE; FIBRIN; FLOW CYTOMETRY; HUMANS; INFANT, NEWBORN; INTEGRIN BETA3; MUSCLE CONTRACTION; MUSCLE, SMOOTH; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PLATELET MEMBRANE GLYCOPROTEINS; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, FIBRONECTIN; RECEPTORS, VITRONECTIN; RECOMBINANT PROTEINS; SURFACE PROPERTIES; VITRONECTIN;

EID: 0032504275     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.83.3.241     Document Type: Article

References (75)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature. 1993;362:801-809.
2. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375.
3. Clarkson TB, Prichard RW, Morgan TM, Petrick GS, Klein PS. Remodeling of coronary arteries in human and nonhuman primates. JAMA. 1994;271:289-294.
4. Kakuta T, Currier JW, Horten K, Faxon DP. Failure of compensatory enlargement, not neointimal formation, accounts for lumen narrowing after angioplasty in the atherosclerotic rabbit [abstract]. Circulation. 1993;88(suppl I):I-619.
5. Weissman NJ, Mendelsohn FO, Palacios IF, Weyman AE. Development of coronary compensatory enlargement in vivo: sequential assessments with intravascular ultrasound. Am Heart J. 1995;130:1283-1285.
6. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.
7. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
8. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69: 377-381.
9. Davies MJ. Acute coronary thrombosis: the role of plaque disruption and its initiation and prevention. Eur Heart J. 1995;17:3-7.
10. Nermerson Y. Tissue factor: then and now. Thromb Haemost. 1995;74: 180-184.
11. Rubin E. Blood Vessels: Pathology. Philadelphia, Pa: JB Lippincott Co; 1988:452-495.
12. Smith EB. Fibrin deposition and fibrin degradation products in atherosclerotic plaques. Thromb Res. 1994;75:329-335.
13. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation. 1995;92:1355-1374.
14. Raghow R. The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J. 1994;8:823-831.
15. Shekhonin BV, Tararak EM, Samokhin GP, Mitkevitch OV, Mazurov AV, Vinogradov DV, Vlasik TN, Kalantarov GF, Koteliansky VE. Visualization of apoB, fibrinogen/fibrin, and fibronectin in the intima of normal and human aorta and large arteries and during atherosclerosis. Atherosclerosis. 1990;82:213-226.
16. Bini A, Kudryk BJ. Fibrinogen and fibrin in the arterial wall. Thromb Res. 1994;75:337-341.
17. Shainoff JR, Page IH. Deposition of modified fibrinogen within the aortic intima. Atherosclerosis. 1972;16:287-305.
18. Valenzuela R, Shainoff JR, DiBello PM, Urbanic DA, Anderson JM, Matsueda GR, Kudryk BJ. Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas. Am J Pathol. 1992;141:861-880.
19. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J. 1990;4:2868-2880.
20. Haas TA, Plow EF. Integrin-ligand interactions: a year in review. Curr Opin Cell Biol. 1994;6:656-662.
21. Ruosolathi E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987;238:491-497.
22. Wright SD, Weitz JI, Huang AJ, Levin SM, Silverstein SC, Loike JD. Complement receptor type three (CD11b/Cd18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci USA. 1988;85:7734-7738.
23. Peerschke EI. The platelet fibrinogen receptor. Semin Hematol. 1985;22: 241-249.
24. Altieri DC, Bader R, Mannucci PM, Edgington TS. Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition for fibrinogen. J Cell Biol. 1988;107:1893-1900.
25. Marshall JF, Rutherford DC, McCartney ACE, Mitjans F, Goodman SL, Hart IR. αvβ1 is a receptor for vitronectin and fibrinogen, and acts with a5b1 to mediate spreading on fibronectin. J Cell Sci. 1995;108: 1227-1238.
26. Neugebauer KM, Venstrom KA, Reichardt LF. Adhesion of a chicken myeloblast cell line to fibrinogen and vitronectin through a β1-class integrin. J Cell Biol. 1992;116:809-815.
27. Suehiro K, Gailit J, Plow EF. Fibrinogen is a ligand for integrin α5β1 on endothelial cells. J Biol Chem. 1997;272:5360-5366.
28. Barbieri B, Balconi G, Dejana E, Donati MB. Evidence that vascular endothelial cells can induce the retraction of fibrin clots (41260). Proc Soc Exp Biol Med. 1981;168:204-207.
29. Chen Y-P, O'Toole TE, Leong L, Liu B-Q, Diaz-Gonzalez F, Ginsberg MH. β3 integrin-mediated fibrin clot retraction by nucleated cells: differing behavior of αIIβ3 and αvβ3. Blood. 1995;86:2606-2615.
30. Katagiri Y, Hiroyama T, Akamatsu N, Suzuki H, Yamazaki H, Tanoue K. Involvement of αvβ3 integrin in mediating fibrin gel retraction. J Biol Chem. 1995;270:1785-1790.
31. Ylanne J, Chen Y, O'Toole TE, Loftus JC, Takada Y, Ginsberg MH, Distinct functions of integrin α and β subunit cytoplasmic domains in cell spreading and formation of focal adhesions. J Cell Biol. 1993;122: 223-233.
32. Cheresh DA, Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen and von Willebrand factor. J Biol Chem. 1987;262:17703-17711.
33. Wayner EA, Pardo AG, Humphries MJ, McDonald JA, Carter WG. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (cs-1) in plasma fibronectin. J Cell Biol. 1989;109:1321-1330.
34. de Vries JE, Keizer GD, te Velde AA, Voordouw A, Ruiter D, Rümke P, Spits H, Figdor CG. Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells. Int J Cancer. 1986;38:465-473.
35. Caixia S, Stewart S, Wayner E, Carter W, Wilkins J. Antibodies to different members of the β1(CD29) integrins induce homotypic and heterotypic cellular aggregation. Cell Immunol. 1991;138:216-228.
36. Giancotti FG, Ruoslahti E. Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell. 1990;60:849-859.
37. Carter WG, Wayner EA, Bouchard TS, Kaur P. The role of integrins α2β1 and α3β1 in cell-cell and cell-substrate adhesion of human epidermal Cells. J Cell Biol. 1990;110:1387-1404.
38. Wayner EA, Carter WG, Piotrowicz RS, Kunicki TJ. The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellular matrix: preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibit cell adhesion to fibronectin and react with platelet glycoproteins Ic-IIa. J Cell Biol. 1988;107: 1881-1891.
39. Wayner EA, Orlando RA, Cheresh DA. Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol. 1991;113:919-929.
40. Wayner EA, Carter WG. Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and common beta subunits. J Cell Biol. 1987;105: 1873-1884.
41. Pierschbacher MD, Ruoslahti E. Influence of sterochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J Biol Chem. 1987;262:17294-17298.
42. Pierschbacher MD, Hayman EG, Ruoslahti E. Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule. Cell. 1981;26:259-267.
43. Akiyama SK, Yamada SS, Chen WT, Yamada KM. Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization. J Cell Biol. 1989;109:863-875.
44. Akiyama SK, Larjava H, Yamada KM. Differences in the biosynthesis and localization of the fibronectin receptor in normal and transformed cultured human cells. Cancer Res. 1990;50:1601-1607.
45. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985;76:101-108.
46. Coller BS, Scudder LR. Inhibition of dog platelet function by in vivo infusion of F(ab′)2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood. 1985;66:1456-1459.
47. Investigators TE. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
48. Arroyo AG, S'anchez-Mateos P, Campanero MR, Mart'in-Padura I. Dejana E, S'anchez-Madrid F. Regulation of the VLA integrin-ligand interactions through the beta 1 subunit. J Cell Biol. 1992;117:659-670.
49. Bergelson JM, Chan BM, Finberg RW, Hemler ME. The integrin VLA-2 binds echovirus 1 and extracellular matrix ligands by different mechanisms. J Clin Invest. 1993;92:232-239.
50. Wang A, Yokosaki Y, Ferrando R, Balmes J, Sheppard D. Differential regulation of airway epithelial integrins by growth factors. Am J Respir Cell Mol Biol. 1996;15:664-672.
51. Damsky CH, Fitzgerald ML, Fisher SJ. Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo. J Clin Invest. 1992;89:210-222.
52. Preissner KT, Holzhuter S, Justus C, Muller-Berghaus G. Identification and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood. 1989;74:1989-1996.
53. Real FX, Houghton AN, Albino AN, Cordon-Cardo C, Melamed MR, Oettgen HF, Old LJ. Surface antigens on melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparisons of antigen expression in cultured cells and tissues. Cancer Res. 1985;45:4401-4411.
54. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. J Clin Invest. 1995;95: 713-724.
55. Perez-Reyes N, Halbert CL, Smith PP, Benditt EP, McDougall JK. Immortalization of primary human smooth muscle cells. Proc Natl Acad Sci U S A. 1992;89:1224-1228.
56. Engvall E, Ruoslahti E. Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. Int J Cancer. 1977;20:1-5.
57. Vuento M, Vaheri A. Purification of fibronectin by affinity chromatography. Biochem J. 1979;183:331-337.
58. Gorkun OV, Veklich YI, Weisel JW, Lord ST. The conversion of fibrinogen to fibrin: recombinant fibrinogen typifies plasma fibrinogen. Blood. 1997;89:4407-4414.
59. Rooney MM, Parise LV, Lord ST. Dissecting clot retraction and platelet aggregation. J Biol Chem. 1996;271:8553-8555.
60. Liaw L, Almeda M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res. 1994;74:214-224.
61. Topol EJ. Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am Heart J. 1995;130:666-672.
62. Courtman DW, Schwartz SM, Hart CE. Sequential injury of the rabbit abdominal aorta induces intramural coagulation and luminal narrowing independent of intimai mass: extrinsic pathway inhibition inhibits luminal narrowing. Circ Res. 1998;82:996-1006.
63. Giltay JC, Mourik JAV. Structure and function of endothelial cell integrins. Haemostasis. 1988;18:376-389.
64. Smith RA, Mosesson MW, Rooney MM, Lord ST, Daniels AV, Gartner TK. The role of putative fibrinogen A-alpha, B-beta and gamma-A chain integrin binding sites in endothelial cell mediated clot contraction. J Biol Chem. 1997;272:22080-22085.
65. Belkin VM, Belkin AM, Koteliansky VE. Human smooth muscle VLA-1 integrin: purification, substrate specificity, localization in aorta, and expression during development. J Cell Biol. 1990;111:2159-2170.
66. Gotwals PJ, Chi-Rosso G, Lindner V, Yang J, Ling L, Fawell SE, Koteliansky VE. The α1β1 integrin is expressed during neointima formation in rat arteries and mediates collagen matrix reorganization. J Clin Invest. 1996;97:1-9.
67. Cremona O, Savoia P, Marchisio PC, Gabbiani B, Chapponier C. The α6 and β4 integrin subunits are expressed by smooth muscle cells of human small vessels: a new localization in mesenchymal cells. J Histochem Cytochem. 1994;42:1221-1228.
68. Mechtersheimer G, Barth T, Quentmeier A, Moller P. Differential expression of β1 integrins in nonneoplastic smooth and striated muscle cells and in tumors derived from these cells. Am J Pathol. 1994;144: 1172-1182.
69. Clyman RI, MacDonald KA, Kramer RH. Integrin receptors on aortic-smooth muscle cells mediate adhesion to fibronectin, laminin and collagen. Circ Res. 1990;67:175-186.
70. 3, integrin expression in normal and atherosclerotic artery. Circ Res. 1995; 77:1129-1135.
71. Ikari Y, Hatsukami TS, Alpers CE, Yee KO, Giachelli CM, Schwartz SM. Alpha V beta 3 integrin is rarely expressed on migrating smooth muscle cells into fibrin matrix in human carotid arteries [abstract]. Circulation. 1997;96(suppl I):I-667.
72. Skinner MP, Raines EW, Ross R. Dynamic expression of α1β1 and α1β2 integrin receptors by human vascular smooth muscle cells. Am J Pathol. 1994;145:1070-1081.
73. Xu J, Clark RAF. Extracellular matrix alters PDGF regulation of fibroblast integrins. J Cell Biol. 1996;132:239-249.
74. Naito M, Hayashi T, Kuzuya M, Funaki C, Asai K, Kuzuya F. Effects of fibrinogen and fibrin on the migration of vascular smooth muscle cells in vitro. Atherosclerosis. 1990;83:9-14.
75. Naito M, Funaki C, Hayashi T, Yamada K, Asai K, Yoshimine N, Kuzuya F. Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cells. Atherosclerosis. 1992;96:227-234.